ivabradine has been researched along with methyldopa in 1 studies
| Studies (ivabradine) | Trials (ivabradine) | Recent Studies (post-2010) (ivabradine) | Studies (methyldopa) | Trials (methyldopa) | Recent Studies (post-2010) (methyldopa) |
|---|---|---|---|---|---|
| 1,143 | 197 | 833 | 3,719 | 420 | 143 |
| Protein | Taxonomy | ivabradine (IC50) | methyldopa (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 5.228 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 5.176 | |
| Polyunsaturated fatty acid lipoxygenase ALOX15 | Oryctolagus cuniculus (rabbit) | 2.126 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mar, PL; Raj, SR | 1 |
1 review(s) available for ivabradine and methyldopa
| Article | Year |
|---|---|
Postural Orthostatic Tachycardia Syndrome: Mechanisms and New Therapies.
Topics: Adrenergic beta-Antagonists; Cardiovascular Agents; Clonidine; Combined Modality Therapy; Female; Humans; Ivabradine; Male; Methyldopa; Postural Orthostatic Tachycardia Syndrome; Quality of Life; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2020 |